

WHAT IS CLAIMED IS

Sub B1
1. A method of treating diseases associated with elevated levels of Tac-positive cells in humans, comprising administering to an afflicted human, a therapeutic amount of ⁹⁰Y-conjugated anti-Tac monoclonal antibody to eliminate disease-associated Tac-positive cells without affecting normal cells, wherein the therapeutic amount comprises 2-100 mg of anti-Tac wherein 5-15 mCi ⁹⁰Y conjugate is provided.

2. The method of claim 1 wherein the disease associated with Tac-positive cells is a T-cell mediated disorder.

3. The methods of claim 2 wherein T-cell mediated disorder is Adult-T-Cell Leukemia, autoimmune dysfunction, or allograft incompatibility.

4. The method of claim 3 wherein said disorder is Adult T-Cell Leukemia.

5. The method of claim 3 wherein said disorder is autoimmune dysfunction.

6. The method of claim 3 wherein said disorder is allograft incompatibility.

7. The method of claim 2 wherein the T-cell mediated disorder is cutaneous T-cell lymphoma.

8. The method of claim 2 wherein the T-cell mediated disorder is peripheral T-cell lymphoma.

9. The method of claim 8 wherein the peripheral T-cell lymphoma is T-cell chronic lymphocytic

leukemia.

10. The method of claim 8 wherein the peripheral T-cell lymphoma is anaplastic large cell lymphoma.

11. The method of claim 7 wherein the cutaneous T-cell lymphoma is mycosis fungoides.

12. The method of claim 7 wherein the cutaneous T-cell lymphoma is Sézary syndrome.

13. The method of claim 1 wherein the Tac associated disease is a B-cell malignancy.

14. The method of claim 13 wherein the B-cell malignancy is hairy cell B-cell leukemia.

15. The method of claim 1 wherein an effective amount of G-CSF is also provided.

16. The method of claim 1 wherein the therapeutic amount is repeated in separate doses.

17. The method of claim 1 wherein the anti-Tac antibody is humanized.

18. The method of claim 1, wherein the therapeutic amount of ⁹⁰Y-conjugated antibody is followed by a second treatment of 100 mg of unconjugated anti-Tac antibody.

19. A method of treating diseases associated with elevated levels of Tac-positive cells in humans, comprising administering to an afflicted human a

therapeutic amount of cytotoxin conjugated anti-Tac antibody to eliminate disease-associated Tac-positive cells without affecting normal cells, wherein a therapeutic amount comprises 10-100 $\mu\text{g/kg}$ anti-Tac doses.

20. The method of claim 19, wherein said cytotoxin is selected from the group consisting of ricin-A and pseudomonas toxin.

21. The method of claim 20 wherein said cytotoxin is ricin-A.

22. The method of claim 19 wherein the cytotoxin conjugated anti-Tac antibody is anti-Tac(Fv)-PE.

23. The method of claim 19, wherein the cytotoxin conjugated anti-Tac antibody is anti-Tac-PE38.

24. A pharmaceutical composition comprising a cytotoxin-conjugated anti-Tac preparation and a suitable excipient, provided in an effective dose.

25. The pharmaceutical composition of claim 24 wherein the cytotoxin conjugated anti-Tac preparation comprises ^{90}Y -conjugated anti-Tac, wherein the effective dosage comprises 2-100 mg anti-Tac wherein 5-15 mCi ^{90}Y conjugate is provided.

Sub
A3
add
C1

add
D1